Literature DB >> 24467262

Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.

Amanda H Seipel1, Brett Delahunt, Hemamali Samaratunga, Mahul Amin, Joel Barton, Daniel M Berney, Athanase Billis, Liang Cheng, Eva Comperat, Andrew Evans, Samson W Fine, David Grignon, Peter A Humphrey, Cristina Magi-Galluzzi, Rodolfo Montironi, Isabell Sesterhenn, John R Srigley, Kiril Trpkov, Theo van der Kwast, Murali Varma, Ming Zhou, Amar Ahmad, Sue Moss, Lars Egevad.   

Abstract

AIMS: Ductal adenocarcinoma of the prostate (DAC) is clinically important, because its behaviour may differ from that of acinar adenocarcinoma. Our aims were to investigate the interobserver variability of this diagnosis among experts in uropathology and to define diagnostic criteria. METHODS AND
RESULTS: Photomicrographs of 21 carcinomas with ductal features were distributed among 20 genitourinary pathologists from eight countries. DAC was diagnosed by 18 observers (mean 13.2 cases, range 6-19). In 11 (52%) cases, a 2/3 consensus was reached for a diagnosis of DAC, and in five (24%) there was consensus against. In DAC, the respondents reported papillary architecture (86%), stratification of nuclei (82%), high-grade nuclear features (54%), tall columnar epithelium (53%), elongated nuclei (52%), cribriform architecture (40%), and necrosis (7%). The most important diagnostic feature reported for DAC was papillary architecture (59%), whereas nuclear and cellular features were considered to be most important in only 2-11% of cases. The most common differential diagnoses were intraductal prostate cancer (52%), high-grade PIN (37%), and acinar adenocarcinoma (17%). The most common reason for not diagnosing DAC was lack of typical architecture (33%).
CONCLUSIONS: Papillary architecture was the most useful diagnostic feature of DAC, and nuclear and cellular features were considered to be less important.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ductal cancer; pathology; prostate cancer; prostatectomy

Mesh:

Year:  2014        PMID: 24467262     DOI: 10.1111/his.12382

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

1.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 2.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 3.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 4.  Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Authors:  Nithesh Ranasinha; Altan Omer; Yiannis Philippou; Eli Harriss; Lucy Davies; Ken Chow; Paolo M Chetta; Andrew Erickson; Timothy Rajakumar; Ian G Mills; Richard J Bryant; Freddie C Hamdy; Declan G Murphy; Massimo Loda; Christopher M Hovens; Niall M Corcoran; Clare Verrill; Alastair D Lamb
Journal:  BJUI Compass       Date:  2021-01-05

5.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

6.  Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Previn Gulavita; Shaheed W Hakim; Nicola Schieda; Rodney H Breau; Chris Morash; Daniel T Keefe; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

Review 7.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

8.  Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy.

Authors:  Mengzhu Liu; Kun Jin; Shi Qiu; Pengyong Xu; Mingming Zhang; Wufeng Cai; Xiaonan Zheng; Lu Yang; Qiang Wei
Journal:  Asian J Urol       Date:  2020-05-23

9.  Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.

Authors:  Riccardo Laudicella; Jan H Rüschoff; Niels J Rupp; Irene A Burger; Daniela A Ferraro; Muriel D Brada; Daniel Hausmann; Iliana Mebert; Alexander Maurer; Thomas Hermanns; Daniel Eberli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-18       Impact factor: 10.057

10.  HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker.

Authors:  Cheol Keun Park; Su-Jin Shin; Yoon Ah Cho; Jin Woo Joo; Nam Hoon Cho
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.